We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

94 hedge funds and large institutions have $394M invested in Lumos Pharma, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more call options, than puts

Call options by funds: $32.5M | Put options by funds: $13.8M

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

77% more capital invested

Capital invested by funds: $223M → $394M (+$171M)

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

13% more funds holding

Funds holding: 8394 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
94
Holders Change
+11
Holders Change %
+13.25%
% of All Funds
2.72%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
20
Increased
36
Reduced
25
Closed
9
Calls
$32.5M
Puts
$13.8M
Net Calls
+$18.8M
Net Calls Change
-$22.4M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
51
PDT Partners
New York
$463K +$554K +1,812 New
ANTB
52
AMG National Trust Bank
Colorado
$452K
PAM
53
Paradigm Asset Management
New York
$452K -$40.7K -133 -7%
DekaBank Deutsche Girozentrale
54
DekaBank Deutsche Girozentrale
Germany
$437K +$27.2K +89 +5%
EMG
55
Ellington Management Group
Connecticut
$432K +$516K +1,689 New
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$431K -$14.1K -46 -3%
CCM
57
Coe Capital Management
Illinois
$426K +$510K +1,667 New
RJA
58
Raymond James & Associates
Florida
$416K -$312K -1,022 -39%
Deutsche Bank
59
Deutsche Bank
Germany
$411K +$103K +337 +26%
MLICM
60
Metropolitan Life Insurance Company (MetLife)
New York
$396K -$122K -398 -20%
EIM
61
Essex Investment Management
Massachusetts
$389K +$465K +1,522 New
NFA
62
Nationwide Fund Advisors
Ohio
$382K -$190K -620 -29%
Goldman Sachs
63
Goldman Sachs
New York
$361K +$278K +911 +182%
FAM
64
Fenimore Asset Management
New York
$350K
BIM
65
Baldwin Investment Management
Pennsylvania
$341K
AIG
66
American International Group
New York
$326K +$9.48K +31 +2%
Wells Fargo
67
Wells Fargo
California
$318K -$163K -534 -30%
BT
68
Bankers Trust
Iowa
$314K -$41.6K -136 -10%
TAM
69
Tocqueville Asset Management
New York
$312K +$363K +1,189 +3,603%
D.E. Shaw & Co
70
D.E. Shaw & Co
New York
$293K -$1.66M -5,443 -83%
PCC
71
Park Circle Company
Maryland
$284K +$340K +1,111 New
BA
72
BlackRock Advisors
Delaware
$274K +$42.8K +140 +15%
Citadel Advisors
73
Citadel Advisors
Florida
$271K +$5.81K +19 +2%
Citigroup
74
Citigroup
New York
$191K -$140K -458 -38%
BG
75
BlackRock Group
United Kingdom
$173K +$207K +676 New

LUMO Hedge Fund Activity: Q1 2014 in Review

94 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2014, worth a combined $394M — up 77% from $223M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new LUMO positions and 9 closed out — a net gain of 11 holders — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $78.6M. The largest seller was Millennium Management, exiting entirely with an estimated $12.1M sold.

  • 94 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2014, up from 83 in Q4 2013.
  • Funds reported $394M of Lumos Pharma, Inc. Common Stock stock for Q1 2014, up 77% quarter-over-quarter.
  • 20 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2014 and 9 closed out, a net change of +11 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2014 was Fidelity Investments, an estimated $78.6M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q1 2014 was Millennium Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q1 2014.